1786 — Scivision Biotech Share Price
0.000.00%
Last trade - 00:00- TWD6.74bn
- TWD6.09bn
- TWD883.31m
- 98
- 28
- 86
- 83
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.52 | ||
| Price to Tang. Book | 3.52 | ||
| Price to Free Cashflow | 28.39 | ||
| Price to Sales | 7.56 | ||
| EV to EBITDA | 19.24 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.3% | ||
| Return on Equity | 13.75% | ||
| Operating Margin | 28.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 466.88 | 505.54 | 557.35 | 712.99 | 883.31 | 1,033 | n/a | 15.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +14.9 | -26.06 | +5.29 | +51.23 | +37.41 | +59.09 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
Directors
- Kaicheng Han CHM
- Zongwei Pan DGM
- Ruling Guo DGM
- Wenjuan Liu OTH
- Guojian Fang DRC
- Taiwei Han DRC
- Jieqing Huang DRC
- Minggong Yang DRC
- Shulan Yang Li DRC
- Rongchao Chen IND
- Shuicong Chen IND
- Zugang Lei IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 12th, 2001
- Public Since
- December 29th, 2010
- No. of Employees
- 64
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 71,854,697
- Address
- No.1, South 1st Road, KAOHSIUNG, 806
- Web
- https://www.scivision.com.tw/
- Phone
- +886 78232258
- Auditors
- Ernst & Young LLP
Upcoming Events for 1786
Similar to 1786
Apex Biotechnology
Taiwan Stock Exchange
Wellell
Taiwan Stock Exchange
Bionime
Taiwan Stock Exchange
Bonraybio Co
Taiwan Stock Exchange
CHC Healthcare
Taiwan Stock Exchange
FAQ
What is the Scivision Biotech share price?
As of Today at 23:07 UTC, shares in Scivision Biotech are trading at TWD92.90. This share price information is delayed by 15 minutes.
How has the Scivision Biotech share price performed this year?
Shares in Scivision Biotech last closed at TWD92.90 and the price had moved by -15.16% over the past 365 days. In terms of relative price strength the Scivision Biotech share price has underperformed the FTSE Developed Asia Pacific Index by -14.19% over the past year.
What are the analyst and broker recommendations for Scivision Biotech?
The overall consensus recommendation for Scivision Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Scivision Biotech dividend yield?
The Scivision Biotech dividend yield is 3.49% based on the trailing twelve month period.
Does Scivision Biotech pay a dividend?
Last year, Scivision Biotech paid a total dividend of TWD3.24, and it currently has a trailing dividend yield of 3.49%.Looking ahead, the next dividend pay date is 2025-05-29.
When does Scivision Biotech next pay dividends?
We do not have data on when Scivision Biotech is to next pay dividends. The historic dividend yield on Scivision Biotech shares is currently 3.49%.
How do I buy Scivision Biotech shares?
To buy shares in Scivision Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Scivision Biotech?
As of the previous close price of TWD92.90, shares in Scivision Biotech had a market capitalisation of TWD6.74bn.
Where are Scivision Biotech shares listed?
Here are the trading details for Scivision Biotech:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1786
What kind of share is Scivision Biotech?
Based on an overall assessment of its quality, value and momentum Scivision Biotech is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Scivision Biotech share price forecast for 2025?
The analyst consensus target price for shares in Scivision Biotech is TWD144.60. That is 55.65% above the last closing price of TWD92.90.
Analysts covering Scivision Biotech currently have a consensus Earnings Per Share (EPS) forecast of TWD5.25 for the next financial year.
Find out moreWhat is the trend in the Scivision Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scivision Biotech. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -5.35%.
As of the last closing price of TWD92.90, shares in Scivision Biotech were trading -17.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Scivision Biotech PE Ratio?
The Scivision Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD92.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Scivision Biotech?
Scivision Biotech's management team is headed by:
- Kaicheng Han - CHM
- Zongwei Pan - DGM
- Ruling Guo - DGM
- Wenjuan Liu - OTH
- Guojian Fang - DRC
- Taiwei Han - DRC
- Jieqing Huang - DRC
- Minggong Yang - DRC
- Shulan Yang Li - DRC
- Rongchao Chen - IND
- Shuicong Chen - IND
- Zugang Lei - IND